virus
constitut
simplest
abund
life
form
replic
virus
larg
depend
deliveri
genom
host
cell
usurp
function
target
cell
produc
protein
requir
form
viral
progeni
mechan
virus
appropri
cellular
function
predict
involv
disrupt
respons
induct
diseas
virusinfect
individu
addit
viral
protein
host
factor
also
requir
facilit
replic
virus
typic
antivir
gene
therapi
aim
deploy
dna
rna
achiev
therapeut
effect
inhibit
express
viral
host
factor
gene
timelin
signific
develop
ongo
research
effort
gene
therapi
viral
infect
illustr
figur
capac
virus
bypass
depend
host
factor
highli
constrain
therefor
inhibit
function
host
factor
use
suppress
emerg
escap
pathogen
use
develop
gene
therapi
infect
hepat
c
viru
hcv
use
approach
appropri
target
select
import
target
host
factor
import
cellular
function
silenc
may
caus
toxic
anoth
method
provid
high
barrier
viral
infect
simultan
inhibit
multipl
viral
target
use
combinatori
approach
type
diseas
caus
viral
infect
vari
depend
characterist
individu
pathogen
exampl
human
immunodefici
viru
hiv
tropism
cell
immun
system
manifest
acquir
immun
defici
syndrom
result
insidi
virusinduc
deplet
infect
host
cell
contrast
infect
ebola
viru
follow
rapid
usual
fulmin
cours
although
prognosi
case
ebola
viru
infect
grave
pathogen
persist
success
treatment
cur
differ
situat
infect
stabl
provir
replic
intermedi
remain
embed
genom
infect
host
cell
make
elimin
viru
difficult
although
infect
virus
remain
signific
global
caus
public
health
problem
advanc
treatment
particularli
impress
past
year
sever
improv
antivir
therapi
made
mani
diseas
effect
manag
antivir
compris
small
molecul
demonstr
particularli
good
efficaci
rang
pathogen
prophylact
immun
prevent
measur
behavior
modif
minim
risk
transmiss
virus
also
contribut
limit
spread
viral
infect
despit
advanc
current
therapeut
inadequ
cur
efficaci
certain
viral
infect
like
diseas
caus
pathogen
remain
problemat
mani
year
mutat
may
chang
properti
exist
virus
new
pathogen
like
emerg
henc
flexibl
technolog
allow
rapid
develop
antivir
base
ration
design
particularli
import
counter
seriou
health
problem
may
result
gene
therapi
potenti
effect
rang
exist
emerg
virus
technolog
may
also
complement
augment
efficaci
current
antivir
drug
howev
gene
therapi
still
face
signific
hurdl
wide
implement
treatment
viral
infect
particularli
import
specif
antivir
nucleic
acid
target
concern
effici
safeti
deliveri
cost
manufactur
capabl
mileston
major
area
ongo
technolog
develop
indic
aav
adenoassoci
viru
sgrna
singl
guid
rna
virus
essenti
replic
suscept
antivir
gene
therapi
addit
direct
target
viral
gene
host
factor
gene
transfer
immunebas
treatment
prophylaxi
potenti
counter
mani
virus
chapter
rel
eas
gener
sequenc
express
appropri
antigen
abil
induc
humor
cellmedi
arm
immun
respons
advantag
use
proteinbas
vaccin
gene
transfer
use
dna
transfect
recombin
viral
vector
deriv
poxvirus
becom
popular
elicit
immun
respons
efficaci
approach
continu
improv
use
procedur
effect
immunostimul
gener
easi
implement
alreadi
test
clinic
trial
perform
resourcepoor
set
although
complex
vector
immunoprophylaxi
vip
modif
immun
cell
engin
cell
receptor
tcr
chimer
antigen
receptor
car
excit
new
develop
potenti
antivir
util
advanc
antivir
gene
therapi
made
steadi
accumul
knowledg
result
signific
breakthrough
discoveri
figur
two
moment
advanc
field
develop
technolog
base
gene
edit
chapter
har
natur
occur
rna
interfer
rnai
pathway
chapter
gene
edit
process
specif
target
dna
sequenc
alter
inhibit
viral
replic
therapi
base
technolog
applic
direct
inactiv
viral
dna
replic
intermedi
produc
prolifer
hepat
b
viru
hbv
inhibit
host
factor
requir
replic
particular
viru
rnai
endogen
gene
regulatori
mechan
typic
caus
posttranscript
gene
silenc
artifici
rnai
activ
compris
mimic
intermedi
pathway
contain
homolog
intend
target
use
success
inhibit
viral
gene
express
exploit
rnai
gene
edit
gener
consider
enthusiasm
technolog
advanc
use
clinic
trial
treatment
viral
infect
includ
caus
hbv
effect
method
inhibit
viral
gene
express
includ
use
antisens
oligonucleotid
aptam
rnase
p
substrat
express
synthet
rnai
activ
util
success
variou
viral
infect
consider
effort
gone
ensur
good
specif
potenc
silenc
viral
cognat
use
pol
iii
promot
transcrib
rna
form
short
hairpin
rna
shrna
structur
mimic
precursor
microrna
premir
particularli
popular
howev
demonstr
overexpress
hbvtarget
shrna
could
result
fatal
toxic
mice
import
caveat
research
field
sinc
observ
variou
configur
express
rnai
activ
engin
improv
control
product
antivir
use
antivir
mimic
primari
microrna
primir
shown
promis
hbv
hcv
rnai
activ
may
transcrib
induc
tissuespecif
pol
ii
promot
artifici
primir
multimer
result
combinatori
silenc
improv
efficaci
provid
greater
barrier
viral
escap
mimic
earli
intermedi
rnai
pathway
function
coupl
process
primir
mimic
downstream
step
pathway
thought
improv
potenc
better
silenc
antivir
allow
use
lower
dose
candid
therapeut
diminish
offtarget
effect
develop
use
synthet
rnai
activ
also
impress
typic
synthet
rnai
activ
compris
short
complementari
strand
rna
constitut
short
interf
rna
sirna
variou
chemic
modif
use
augment
silenc
diminish
immunostimul
stabil
gene
silenc
synthet
procedur
also
adapt
purpos
one
interest
applic
coupl
target
aptam
synthet
sirna
enabl
specif
deliveri
virusinfect
cell
avail
new
method
bioinformat
analysi
also
import
advanc
rnaibas
antivir
therapi
seed
region
guid
strand
potenti
therapeut
sirna
requir
effect
translat
silenc
likelihood
nonspecif
inhibit
cellular
target
may
high
howev
avail
vast
sequenc
databas
analyt
algorithm
allow
design
antivir
rnai
activ
minim
interact
offtarget
site
ultim
success
rnaibas
antivir
therapi
like
depend
demonstr
superior
effici
compar
exist
therapi
addit
adapt
silenc
strategi
attain
inhibit
requir
cur
effect
import
consider
illustr
exampl
develop
rnaibas
therapi
treatment
persist
hbv
infect
clinic
trial
progress
use
nonvir
formul
contain
synthet
rnai
activ
treat
hbv
infect
http
wwwarrowheadresearchcomprogramsoverview
suppress
viral
replic
better
good
licens
drug
need
demonstr
addit
gene
silenc
mechan
perman
abil
treatment
achiev
durabl
effect
lead
cur
elimin
viral
replic
intermedi
import
transient
rnaibas
silenc
may
better
suit
treatment
rna
virus
stabl
dna
replic
intermedi
antivir
gene
edit
technolog
entail
inactiv
dna
sequenc
therefor
adapt
disabl
viral
dna
replic
intermedi
gene
host
factor
requir
viral
prolifer
effect
mutagenesi
virus
essenti
replic
suscept
antivir
gene
therapi
engin
sequencespecif
dnatarget
protein
coupl
nucleas
repeat
cleavag
follow
cellular
errorpron
nonhomolog
end
join
result
mutagenesi
intend
target
earliest
studi
show
feasibl
gene
edit
use
deriv
zinc
finger
protein
zfp
twenti
year
ago
approach
shown
inhibit
express
bcrabl
sequenc
gener
chromosom
transloc
character
chronic
myeloid
leukemia
inhibitori
effect
result
bind
engin
zfp
dna
physic
disrupt
transcript
bcrabl
sequenc
engin
zfp
compris
tandem
arrang
finger
bind
triplet
nucleotid
zinc
finger
nucleas
zfn
typic
gener
fuse
dnabind
domain
nucleas
type
ii
restrict
endonucleas
foki
cut
one
strand
dna
duplex
therefor
complet
zfn
compris
dimer
unit
design
cleav
complementari
strand
intend
target
although
engin
zfn
subject
mani
year
studi
applic
technolog
complic
variabl
effici
target
bind
cleavag
home
endonucleas
he
also
known
meganucleas
may
caus
sequencespecif
cleavag
viral
target
engin
class
nucleas
fraught
technic
difficulti
problem
associ
dual
function
target
bind
dna
cleavag
domain
he
constrain
use
deriv
transcript
activatorlik
effector
tale
includ
tale
nucleas
talen
repressor
tale
overcom
problem
zfn
monom
make
tale
show
context
depend
finger
zfp
circumv
need
screen
larg
panel
engin
protein
identifi
optim
act
editor
altern
engin
nucleas
sequencespecif
transcript
repressor
may
well
find
favor
therapeut
inhibit
viral
gene
express
box
krab
capabl
induc
epigenet
chang
specif
sequenc
dna
caus
longterm
transcript
suppress
substitut
repressor
nucleas
engin
protein
get
around
problem
possibl
mutagen
effect
may
aris
nonspecif
cleavag
host
genom
dna
recent
discoveri
cluster
regularli
interspac
short
palindrom
repeat
crispr
crisprassoci
ca
system
also
gener
enthusiasm
among
research
interest
develop
antivir
gene
edit
engin
nucleas
conveni
sitespecif
cleavag
target
dna
base
interact
singlestrand
rna
guid
target
dna
therefor
approach
obviat
complic
methodolog
entail
gener
sequenc
encod
protein
bind
specif
dna
target
zfn
auspici
potenti
render
autolog
cell
resist
excit
prospect
talen
gener
target
hbv
gene
potenti
antivir
therapi
promis
engin
crisprca
system
also
shown
effect
replic
hbv
cultur
cell
rnai
viral
infect
effici
deliveri
specif
effector
intend
target
import
clinic
applic
gene
edit
except
smaller
sequenc
encod
he
express
cassett
produc
gene
editor
typic
larger
kb
length
moreov
case
zfn
talen
two
cassett
requir
produc
two
monom
make
dimer
nucleas
likewis
typic
engin
crispr
ca
system
compris
two
cassett
one
encod
nucleas
enzym
guid
rna
recombin
adenoassoci
viral
vector
popular
gene
therapi
vector
limit
capac
accommod
transgen
therefor
complet
dimer
nucleas
may
constitut
transduct
cell
two
vector
express
one
monom
altern
complic
deliveri
approach
use
nonvir
vector
nvv
deliv
mrna
encod
gene
editor
subunit
formul
method
limit
size
mrna
may
incorpor
vector
techniqu
becom
commonli
use
use
featur
gene
edit
viral
gene
therapi
transient
express
gene
editor
may
requir
effect
potenti
cur
inhibit
viral
replic
target
alter
introduct
mutat
gene
edit
nucleas
longer
requir
fact
persist
effector
undesir
risk
offtarget
effect
increas
featur
well
suit
use
nvv
deliv
nucleaseencod
mrna
durabl
gene
edit
involv
use
target
transcript
repressor
krab
introduc
epigenet
inhibitori
effect
yet
well
character
transient
express
repressor
may
suffici
caus
intend
durabl
therapeut
inhibit
avoid
unwant
effect
host
genom
may
particularli
use
treatment
chronic
hbv
infect
transcript
repressor
individu
carrier
viru
hbv
dna
often
integr
hepatocyt
genom
nucleasemedi
digest
may
induc
chromosom
transloc
caus
unintend
side
effect
optim
deliveri
nucleic
acid
object
common
advanc
gene
therapi
diseas
locat
virusinfect
cell
pertin
devis
appropri
method
deliv
therapeut
exampl
prospect
antivir
gene
therapi
system
administr
antivir
may
necessari
disabl
hbv
gene
liver
howev
treatment
respiratori
infect
administr
therapeut
formul
airway
usual
effect
two
main
type
deliveri
vehicl
viral
vector
nvv
discuss
detail
chapter
particular
featur
suit
specif
applic
antivir
gene
therapi
viral
vector
effici
carrier
sequenc
encod
express
cassett
wherea
deliveri
vivo
express
cassett
nvv
formul
usual
modest
virus
essenti
exist
nucleic
acid
parasit
evolv
effici
mechan
cellular
deliveri
nucleic
acid
properti
exploit
gener
viral
vector
although
recombin
virus
highli
capabl
vector
drawback
high
cost
product
difficulti
regul
dose
therapeut
induct
mutat
transduc
cell
elicit
neutral
potenti
toxic
immunostimul
durabl
express
particularli
recombin
lentivir
vector
use
achiev
sustain
antivir
effect
util
vector
antivir
applic
narrow
rnabas
antivir
grow
popular
nvv
prefer
vector
deliveri
nucleic
acid
nvv
readili
cross
nuclear
membran
cytoplasm
site
action
antivir
rna
includ
synthet
sirna
mrna
conveni
featur
variou
nvv
develop
includ
lipoplex
formul
polym
conjug
base
use
synthet
compound
nvv
may
prepar
larg
scale
requir
clinic
applic
moreov
rnacontain
nonvir
formul
appeal
limit
immunostimul
avoid
mutagen
effect
dna
attain
adequ
express
immunogen
protein
fewer
cell
need
transduc
deliv
effector
direct
effect
viral
replic
moreov
cell
transduc
may
readili
access
intramuscular
intraderm
deliveri
necessarili
virusinfect
cell
recombin
adenovirus
variou
poxvirus
protein
code
sequenc
within
nvv
electropor
nake
dna
togeth
adjuv
use
success
elicit
antivir
immun
respons
predict
longterm
role
gene
therapi
viral
infect
difficult
apart
mani
technic
challeng
addit
factor
influenc
futur
gener
use
antivir
gene
therapi
altern
treatment
prevent
viral
infect
effect
easili
administ
import
antivir
gene
therapi
may
diminish
exampl
case
could
play
develop
treatment
hcv
infect
recent
progress
hcv
therapi
use
small
molecul
impress
newli
licens
combin
drug
produc
gilead
rapidli
effect
hcv
genotyp
http
harvoni
contain
inhibitor
protein
hcv
administr
patient
avoid
need
includ
regimen
success
implement
new
hcv
treatment
manag
becom
wide
afford
import
gene
therapi
hcv
infect
may
diminish
miravirsen
modifi
oligonucleotid
antisens
shown
good
efficaci
clinic
trial
licens
gener
use
candid
host
factordis
nucleic
acid
like
depend
econom
product
achiev
antivir
efficaci
least
good
recent
licens
antihcv
agent
nevertheless
gene
therapi
continu
import
treat
seriou
infect
cure
use
approach
possibl
elimin
hbv
exampl
gene
therapi
like
play
role
cure
infect
case
chronic
hbv
infect
persist
stabl
coval
close
circular
dna
unaffect
exist
therapi
gene
edit
approach
potenti
provid
mean
disabl
intract
viral
transcript
templat
likewis
use
gene
edit
inactiv
provir
sequenc
render
cell
resist
infect
viru
use
cure
infect
seriou
consider
longterm
prospect
implement
gene
therapi
treatment
viral
infect
relat
practic
use
technolog
resourcepoor
set
infect
virus
caus
seriou
health
problem
hbv
ebola
viru
often
occur
financi
impoverish
commun
gene
therapi
formul
complic
expens
prepar
unlik
necessari
financi
resourc
current
avail
mani
countri
infect
seriou
effect
likewis
gene
therapybas
method
may
difficult
execut
requir
high
level
expertis
implement
exampl
procedur
involv
modif
autolog
progenitor
cell
ex
vivo
select
reinfus
patient
confer
resist
chapter
technolog
highli
special
lack
expertis
would
limit
access
commun
treatment
infect
need
improv
methodolog
advanc
new
technolog
expect
cost
diminish
procedur
perform
gene
therapi
may
becom
simpler
ideal
result
futur
broader
access
technolog
disadvantag
patient
case
use
gene
transfer
immunostimul
prevent
treat
viral
infect
practic
consider
differ
dnabas
vaccin
recombin
viral
vector
use
induc
immun
gener
administ
use
simpler
procedur
give
vaccin
larg
number
peopl
uncompl
long
necessari
cold
chain
requir
met
howev
immunotherapi
use
vip
modifi
cell
express
engin
tcr
car
complex
gene
therapi
target
gene
virus
host
factor
implement
like
requir
simplif
improv
make
technolog
costeffect
wider
use
major
advantag
gene
therapi
abil
develop
antivir
agent
base
applic
becom
simpl
ration
design
principl
case
antivir
gene
therapi
har
rnaibas
silenc
antisens
oligonucleotid
gene
edit
basi
knowledg
sequenc
target
theoret
possibl
develop
gener
method
enabl
rapid
design
antivir
nucleic
acid
therefor
speed
gene
therapi
could
develop
emerg
pathogen
advantag
use
smallmolecul
drug
treat
viral
infect
identifi
effect
small
molecul
antivir
also
guid
ration
design
typic
requir
detail
structur
analysi
viral
protein
target
empir
test
optim
use
therapi
advanc
broader
field
gene
therapi
virolog
synthet
chemistri
molecular
biolog
better
understand
factor
influenc
safeti
deliveri
effici
antivir
action
nucleic
acid
like
reach
import
facilit
implement
effect
therapeut
measur
address
seriou
health
challeng
pose
exist
emerg
pathogen
avail
suitabl
tool
enabl
countermeasur
put
place
turn
import
deal
outbreak
infect
caus
sever
acut
respiratori
syndrom
coronaviru
infect
ebola
viru
gene
therapi
viral
infect
current
pois
excit
phase
signific
success
realiz
full
potenti
power
technolog
tantalizingli
close
signific
goal
like
met
near
futur
turn
influenc
direct
field
